Compound C108
SIGMA/SML2017 - ≥98% (HPLC)
Synonym: 2-
CAS Number: 15533-09-2
Empirical Formula (Hill Notation): C15H14N2O3
Molecular Weight: 270.28
Linear Formula: C15H14N2O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| shipped in | ambient |
| SMILES string | OC1=C(C=CC=C1)C(C)=NNC(C2 |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | −20°C |
| Biochem/physiol Actions: | C108 is a small molecule that exhibits cancer-selective cytotoxicity (Viability = 100%/MCF-10A vs. 50%/BT-474, 67%/4T1, 70%/MDA-MB-231 & MDA-MB-453 post 48 h 1 μM C108 treatment) and synergizes with low dose paclitaxel in reducing ALDH-positive tumor-initiating cells (TIC poulation = 56.6%/control, 60.6%/0.1 μM paclitaxel alone, 47.4%/1 μM C108 alone, 7.3%/combined treatment for 24 h in BT474 breast cancer cultures) by targeting stress granule-associated protein G3BP2 (GAP SH3 domain-binding protein 2). Likewise, C108 pretreatment prior to xenografting greatly reduces BT-474 tumor-initiating frequency (from 1/175 to 1/1103 by limiting dilution xenograft assays) in mice in vivo. G3BP2 is reported to bind and stabilize SART3 mRNA, thereby indirectly regulating the core pluripotency transcription factors Oct-4 and Nanog critically involved in ESC self-renewal and breast tumor initiation. |
| Biochem/physiol Actions: | G3BP2 inhibitor that exhibits cancer-selective toxicity and synergizes with low dose paclitaxel against tumor-initiating cell (TIC) population in breast cancer cultures. |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |